This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Manhattan Associates (MANH) Soars 3.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Manhattan Associates (MANH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Simulations Plus (SLP) Upgraded to Buy: Here's Why
by Zacks Equity Research
Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adobe Systems (ADBE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Adobe (ADBE) delivered earnings and revenue surprises of 2.05% and 0.54%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
by Zacks Equity Research
Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.
Broadcom Inc. (AVGO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Broadcom Inc. (AVGO) delivered earnings and revenue surprises of 1.58% and 3.71%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Autodesk (ADSK) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Autodesk (ADSK) delivered earnings and revenue surprises of 5.06% and 1.46%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
American Software (AMSWA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
American Software (AMSWA) delivered earnings and revenue surprises of 50% and 2.08%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Simulations Plus (SLP) Launches GPX to Advance PBPK Modeling
by Zacks Equity Research
Simulations Plus (SLP) unveils GastroPlus X, which significantly reduces time spent on model setup, data management, and reformatting results.
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
by Zacks Equity Research
For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Simulations Plus' (SLP) second-quarter fiscal 2024 top line is driven by higher revenues in the Software and Services business segments.